Clinical Trial Update: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 liquid-biopsy informed platform trial evaluating treatments for CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer; recruitment is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING